PMC:7461420 / 103909-104506
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T504 | 216-220 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T505 | 231-235 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T506 | 271-280 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T507 | 513-517 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T16 | 137-145 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T17 | 162-167 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T18 | 207-214 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
T19 | 248-249 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T20 | 306-311 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T55784 | 28-38 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T28876 | 375-385 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T17256 | 499-509 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 105-109 | http://purl.obolibrary.org/obo/GO_0003968 | denotes | RdRP |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
3122 | 105-109 | Gene | denotes | RdRP | Gene:43740578 |
3123 | 322-326 | Gene | denotes | ACE2 | Gene:59272 |
3124 | 89-93 | Gene | denotes | Mpro | Gene:8673700 |
3125 | 162-167 | Species | denotes | human | Tax:9606 |
3126 | 178-182 | Species | denotes | CoVs | Tax:11118 |
3127 | 216-224 | Species | denotes | SARS‐CoV | Tax:694009 |
3128 | 231-241 | Species | denotes | SARS‐CoV‐2 | Tax:2697049 |
3129 | 306-311 | Species | denotes | human | Tax:9606 |
3130 | 513-521 | Species | denotes | SARS‐CoV | Tax:694009 |
3131 | 271-280 | Disease | denotes | infection | MESH:D007239 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T953 | 0-183 | Sentence | denotes | As outlined in this review, inhibitors of important viral enzymes or structures, such as Mpro, PLpro, or RdRP have displayed encouraging activity against various human‐infecting CoVs. |
T954 | 184-452 | Sentence | denotes | Since, both contagious viruses, SARS‐CoV‐1 and SARS‐CoV‐2, have a similar mechanism of infection; and both share the same human receptor, ACE2, for viral entry, for example—already developed inhibitors against the former could potentially be used to combat the latter. |
T955 | 453-597 | Sentence | denotes | But despite the efficacy demonstrated by many inhibitors of SARS‐CoV‐1, no specific prophylactic or postexposure therapy is currently available. |